---

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• www.molecularpartners.com
• IPO

Related News

• Allergan and Molecular Partners Enter into an Exclusive License Agreement for MP0112 for the Treatment of Retinal Diseases
• Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-Oncology
• Molecular Partners Reports Positive Results From its First Clinical Studies
• Molecular Partners’ Strategic Partner Allergan Announced Today that EMA has Validated the Marketing